Search review questions

The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by a medical practitioner · pityriasis rosea

Minor participant‐reported adverse events not requiring withdrawal of the treatment · pityriasis rosea

The proportion of participants with good or excellent rash improvement within 2 weeks, as rated by the participant · pityriasis rosea

Serious adverse events, i.e. serious enough to require withdrawal of the treatment · pityriasis rosea

The proportion of participants with resolution of itch within 2 weeks, as rated by the participant · pityriasis rosea

Severe skin drug‐induced rash · patients with HIV‐1 infection and a pre‐established clinical need for treatment with an antiretroviral drug regimen…

Long‐term sequelae · patients with HIV‐1 infection and a pre‐established clinical need for treatment with an antiretroviral drug regimen…

Hospitalisation for drug‐induced skin reaction · patients with HIV‐1 infection and a pre‐established clinical need for treatment with an antiretroviral drug regimen…

SJS/TEN (Stevens‐Johnson syndrome/toxic epidermal necrolysis) · patients with HIV‐1 infection and a pre‐established clinical need for treatment with an antiretroviral drug regimen…

AGEP (acute generalised exanthematous pustulosis) · patients with HIV‐1 infection and a pre‐established clinical need for treatment with an antiretroviral drug regimen…

HSS (hypersensitivity) reaction including SJS/TEN (clinically diagnosed) (6 weeks clinical assessment) · patients with HIV‐1 infection and a pre‐established clinical need for treatment with an antiretroviral drug regimen…

HSS reaction including SJS/TEN (immunologically confirmed) (6 weeks clinical assessment) · patients with HIV‐1 infection and a pre‐established clinical need for treatment with an antiretroviral drug regimen…

Death · patients with HIV‐1 infection and a pre‐established clinical need for treatment with an antiretroviral drug regimen…

Change in severity · infantile seborrhoeic dermatitis (including cradle cap)

Adverse events · infantile seborrhoeic dermatitis (including cradle cap)

Quality of life · infantile seborrhoeic dermatitis (including cradle cap)

Change in severity · infantile seborrhoeic dermatitis (including cradle cap)

Adverse events · infantile seborrhoeic dermatitis (including cradle cap)

Quality of life · infantile seborrhoeic dermatitis (including cradle cap)

Change in severity · infantile seborrhoeic dermatitis (including cradle cap)

Adverse events · infantile seborrhoeic dermatitis (including cradle cap)

Quality of life · infantile seborrhoeic dermatitis (including cradle cap)

Percentage of participants clear or almost clear, i.e. obtaining PASI 100/90 and/or PGA of 0 or 1 in the short term · guttate psoriasis

Percentage of participants with adverse effects and severe adverse effects · guttate psoriasis

Number of relapses of guttate psoriasis or flares within a period of 6 months after the treatment has finished · guttate psoriasis

Percentage of participants achieving a PASI 75 or PGA of 1 or 2 · guttate psoriasis

Improvement in participant satisfaction measures and quality of life assessment measures Overall subjective score on 5 items (appearance of lesions, impairment of daily life, pruritus, burning, and pain) reported through figures · guttate psoriasis

Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · guttate psoriasis

Risk of having at least one relapse at long‐term · guttate psoriasis

Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · chronic plaque psoriasis

Proportion of participants with adverse events and severe adverse events · chronic plaque psoriasis

Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · chronic plaque psoriasis

Proportion of participants achieving PASI 75 or PGA 1 to 2 · chronic plaque psoriasis

Risk of having at least one relapse at long‐term · chronic plaque psoriasis

Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · guttate psoriasis

Proportion of participants with adverse events and severe adverse events · guttate psoriasis

Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · guttate psoriasis

Proportion of participants achieving PASI 75 or PGA 1 to 2 · guttate psoriasis

Proportion of participants with adverse events and severe adverse events · guttate psoriasis

Risk of having at least one relapse at long‐term · guttate psoriasis

Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · chronic plaque psoriasis

Proportion of participants with adverse events and severe adverse events · chronic plaque psoriasis

Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · chronic plaque psoriasis

Proportion of participants achieving PASI 75 or PGA 1 to 2 · chronic plaque psoriasis

Risk of having at least one relapse at long‐term · chronic plaque psoriasis

Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · guttate psoriasis

Proportion of participants achieving PASI 75 or PGA 1 to 2 · guttate psoriasis

Risk of having at least one relapse at long‐term · guttate psoriasis

Time‐to‐resolution: achieving PASI 90 to 100 or PGA 0 to 1 · guttate psoriasis

Proportion of participants with adverse events and severe adverse events · guttate psoriasis